We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel Bacterial Inhibitor Blocks Lysozyme Activity in Model

By LabMedica International staff writers
Posted on 18 Jul 2018
Print article
Image: This photomicrograph reveals the histopathology in an acute case of gonococcal urethritis using Gram-stain technique. This slide demonstrates the non-random distribution of gonococci among polymorphonuclear neutrophils. Note that there are both intracellular and extracellular bacteria in the field of view (Photo courtesy of the CDC).
Image: This photomicrograph reveals the histopathology in an acute case of gonococcal urethritis using Gram-stain technique. This slide demonstrates the non-random distribution of gonococci among polymorphonuclear neutrophils. Note that there are both intracellular and extracellular bacteria in the field of view (Photo courtesy of the CDC).
A team of molecular microbiologists has identified a mechanism by which certain bacteria – in particular the Gram-negative pathogen Neisseria gonorrhoeae – avoid lysozyme destruction.

Lysozyme, also known as muramidase or N-acetylmuramide glycanhydrolase is an antimicrobial enzyme produced by animals that forms part of the innate immune system. Lysozyme is a glycoside hydrolase that catalyzes the hydrolysis of 1,4-beta-linkages between N-acetylmuramic acid and N-acetyl-D-glucosamine residues in peptidoglycan, which is the major component of gram-positive bacterial cell wall. This hydrolysis in turn compromises the integrity of bacterial cell walls causing lysis of the bacteria.

Lysozymes are ubiquitous as the first line of immune defense against microbes in animals. They exert bactericidal action through antimicrobial peptide activity and peptidoglycan hydrolysis. Gram-negative bacteria developed several weapons to battle lysozymes, including inhibitors of c-type lysozymes in the MliC/PliC family and the Neisseria adhesin complex protein (ACP). Until the recent discovery of ACP, no proteinaceous lysozyme inhibitors were reported for the genus Neisseria, including the important human pathogen N. gonorrhoeae.

Investigators at Oregon State University (Corvallis, USA) have changed this picture. In a paper published in the July 5, 2018, online edition of the journal PLOS Pathogens, they described a previously unrecognized gonococcal virulence mechanism involving a protein encoded by the open reading frame ngo1063 that acted to counteract c-type lysozyme and provided a competitive advantage to the microorganism in a gonorrhea mouse model. They named this protein SliC for "surface-exposed lysozyme inhibitor of c-type lysozyme."

Although SliC displayed low overall primary sequence similarity to the MliC/PliC inhibitors, it was found to have a parallel inhibitory mechanism. The investigators showed that SliC was a surface-displayed lipoprotein in N. gonorrhoeae and, through its lysozyme-blocking function, played a critical role in colonization of genital tract mucosae during infection in the female gonorrhea mouse model.

"The infections very often are silent," said senior author Dr. Aleksandra Sikora, assistant professor of pharmacy at Oregon State University. "Up to 50% of infected women do not have symptoms, but those asymptomatic cases can still lead to some very severe consequences for the patient's reproductive health, miscarriage or premature delivery. This is the first time an animal model has been used to demonstrate a lysozyme inhibitor's role in gonorrhea infection. Together, all of our experiments show how important the lysozyme inhibitor is. This is very exciting."

Related Links:
Oregon State University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.